Design and synthesis of immobilized Tamiflu analog on resin for affinity chromatography

Tetrahedron Letters

Volumn 50, Issue 26, 2009, Pages 3205-3208

  Kimura, Yasuaki ^a   Yamatsugu, Kenzo ^a   Kanai, Motomu ^a   Echigo, Noriko ^b   Kuzuhara, Takashi ^b   Shibasaki, Masakatsu ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKUSHIMA BUNRI UNIVERSITY   (Japan)

Author keywords

Abnormal behavior; Affinity chromatography; Immobilization; Neuraminidase; Tamiflu

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR; OSELTAMIVIR DERIVATIVE; RESIN; SIALIDASE; UNCLASSIFIED DRUG; VIRUS ENZYME;

AFFINITY CHROMATOGRAPHY; ARTICLE; BINDING AFFINITY; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG SYNTHESIS; DRUG TARGETING; FUNCTIONAL ASSESSMENT; INFLUENZA; INFLUENZA VIRUS;

ORTHOMYXOVIRIDAE; VERTEBRATA;

EID: 65549152349     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2009.01.142     Document Type: Article

References (30)

1. Kim C.U., Lew W., Williams M.A., Liu H., Zhang L., Swaminathan S., Bischofberger N., Chen M.S., Mendel D.B., Tai C.Y., Laver W.G., and Stevens R.C. J. Am. Chem. Soc. 119 (1997) 681
2. For studies on the synthesis of Tamiflu, see:. Yueng Y.-Y., Hong S., and Corey E.J. J. Am. Chem. Soc. 128 (2006) 6310
3. Fukuta Y., Mita T., Fukuda N., Kanai M., and Shibasaki M. J. Am. Chem. Soc. 128 (2006) 6312
4. Cong X., and Yao Z.-J. J. Org. Chem. 71 (2006) 5365
5. Mita T., Fukuda N., Kanai M., and Shibasaki M. Org. Lett. 9 (2007) 259
6. Yamatsugu K., Kamijo S., Suto Y., Kanai M., and Shibasaki M. Tetrahedron Lett. 48 (2007) 1403
7. Bromfield K.M., Graden H., Hagberg D.P., Olsson T., and Kann N. Chem. Commun. (2007) 3183
8. Satoh N., Akiba T., Yokoshima S., and Fukuyama T. Angew. Chem., Int. Ed. 46 (2007) 5734
9. Shie J.-J., Fang J.-M., Wang S.-Y., Tsai K.-C., Cheng Y.-S.E., Yang A.-S., Su C.-Y., and Wong C.-H. J. Am. Chem. Soc. 129 (2007) 11892
10. Kipassa N.T., Okamura H., Kina K., Hamasa T., and Iwagawa T. Org. Lett. 10 (2008) 815
11. Trost B.M., and Zhang T. Angew. Chem., Int. Ed. 47 (2008) 3759
12. Zutter U., Iding H., Spurr P., and Wirz B. J. Org. Chem. 73 (2008) 4895
13. Shie J.-J., Fang J.-M., and Wong C.-H. Angew. Chem., Int. Ed. 47 (2008) 5788
14. Yamatsugu K., Yin L., Kamijo S., Kimura Y., Kanai M., and Shibasaki M. Angew. Chem., Int. Ed. 48 (2009) 1070
15. Matveenko M., Willis A.C., and Banwell M.G. Tetrahedron Lett. 49 (2008) 7018
16. Ishikawa H., Suzuki T., and Hayashi Y. Angew. Chem., Int. Ed. 48 (2009) 1304
17. For reviews on the synthesis of Tamiflu, see:. Farina N., and Brown J.D. Angew. Chem., Int. Ed. 45 (2006) 7300
18. Shibasaki M., and Kanai M. Eur. J. Org. Chem. 1839 (2008)
19. Izumi Y., Tokuda K., O'Dell K.A., Zorumski C.F., and Narahashi T. Neurosci. Lett. 426 (2007) 54
20. Ishii K., Hamamoto H., Sasaki T., Ikegaya Y., Yamatsugu K., Kanai M., Shibasaki M., and Sekimizu K. Drug Discov. Ther. 2 (2008) 24
21. Morita M., Sone T., Yamatsugu K., Sohotome Y., Matsunaga S., Kanai M., Watanabe Y., and Shibasaki M. Bioorg. Med. Chem. Lett. 18 (2008) 600
22. Usami A., Sasaki T., Satoh N., Akiba S., Yokoshima S., Fukuyama T., Yamatsugu K., Kanai M., Shibasaki M., Matsuki N., and Ikegaya Y. J. Pharamacol. Sci. 106 (2008) 659
23. According to the Ministry of Health, Labor, and Welfare of Japan, there is no relationship between Tamiflu administration and abnormal behaviors based on animal experiments performed by the Chugai Pharmaceutical Company, which sells Tamiflu in Japan. For details, see http://www.mhlw.go.jp/shingi/2007/12/s1210-6.html, http://www.chugai-pharm.co.jp/html/info/071210.html.
24. Rusell R.J., Haire L.F., Stevens D.J., Collins P.J., Lin Y.P., Blackburn G.M., Hay A.J., Gamblin S.J., and Skehel J.J. Nature 443 (2006) 45
25. Collins P.J., Haire L.F., Lin Y.P., Liu J., Rusell R.J., Walker P.A., Skehel J.J., Martin S.R., Hay A.J., and Gamblin S.J. Nature 453 (2008) 1258
26. For the synthesis of 5-azido-1-pentanol, see:. Gracias V., Frank K.E., Milligan G.L., and Aube J. Tetrahedron 53 (1997) 16241
27. The reaction with 4 equiv or 10 equiv of the alcohol gave low yields (approximately 20% and 40%, respectively) of the ether 16.
28. 4 afforded a complex mixture.
29. Approximately, 40% of unreacted 20b was recovered based on NMR analysis of the combined solution phases.
30. Ullrich T., Ghobrial M., Peters C., Billich A., Guerini D., and Nussbaumer P. Chem. Med. Chem. 3 (2007) 356